Spruce Biosciences

Inside the Company

Spruce Biosciences was incorporated in 2014 and is headquartered in South San Francisco, California [Crunchbase]. Regulatory filings identify Richard King as a co-founder and early executive [SEC, September 2020]. The firm's development path follows a classic biotech arc, progressing from venture-backed private research to a public listing. Its key operational milestone was an initial public offering in 2020, which provided the capital to advance its clinical programs [Seeking Alpha, July 2023].

Since going public, the company has navigated the volatile path of clinical-stage drug development. A significant corporate event in July 2025 was a reverse stock split [Spruce Biosciences, July 2025]. The following October, the company secured a $50 million private placement, demonstrating continued investor support for its pipeline [Spruce Biosciences, October 2025]. This was followed by a $60 million public offering in April 2026 [Spruce Biosciences, April 2026].

Recent leadership appointments signal a shift toward commercialization readiness. In March 2026, Spruce appointed Dale Hooks as its Chief Commercial Officer [Spruce Biosciences, March 2026]. The company also appointed Libbie Mansell as Chief Regulatory and Quality Officer [Spruce Biosciences].

Data Accuracy: GREEN -- Company milestones and incorporation details are confirmed by SEC filings and company press releases. Leadership appointments are sourced directly from corporate announcements.

Under the Hood

Spruce Biosciences’s clinical-stage pipeline is built on a dual strategy: targeting rare endocrine disorders with non-steroidal therapies and applying a precision medicine approach to broader neurological conditions. The company’s lead asset, tildacerfont, is a non-steroidal CRF1 receptor antagonist being developed as a disease-modifying therapy for classic congenital adrenal hyperplasia (CAH) in both adults and children [GlobalData]. The core wedge is its potential to reduce the chronic high-dose glucocorticoid steroid burden that is the problematic standard of care for CAH [GlobalData]. Tildacerfont is currently in Phase 2b clinical trials for adult CAH and Phase 2 trials for pediatric CAH [Investing.com]. Separately, the company is developing the same molecule as a precision treatment for major depressive disorder (MDD) in collaboration with HMNC Brain Health, using HMNC’s Cortibon diagnostic to pre-select likely responders [Spruce Biosciences].

The company’s pipeline extends beyond its lead program. Spruce holds an exclusive worldwide license for TA-ERT (tralesinidase alfa), an enzyme replacement therapy for Sanfilippo syndrome type B (MPS IIIB) [Seeking Alpha]. Third-party financial profiles also list SPR202, an anti-corticotrophin releasing hormone monoclonal antibody for CAH, and SPR204, a monoclonal antibody antagonist for post-bariatric hypoglycemia [StockAnalysis, Seeking Alpha].

In 2026, the company announced that the CAHmelia-204 clinical trial for tildacerfont in adult CAH did not achieve its primary efficacy endpoint of absolute change in daily glucocorticoid dose from baseline at week 24 [Spruce Biosciences, 2026].

Data Accuracy: GREEN -- Product claims and pipeline status are confirmed by company press releases, investor materials, and third-party clinical databases.

Market Research

The investment case for Spruce Biosciences is anchored in the persistent, high-value unmet needs of rare endocrine and neurological disorders. Spruce's primary focus, congenital adrenal hyperplasia (CAH), is a rare genetic disorder affecting adrenal steroid production. The standard of care involves lifelong, high-dose glucocorticoid replacement, which carries significant long-term side effects. The company's secondary focus on a precision medicine approach to major depressive disorder (MDD) targets a much larger but notoriously heterogeneous market, attempting to carve out a specific, biomarker-defined patient population.

Metric	Value
Rare Disease Drug Market (2030 est.)	$300B
CAH Patients (US & EU est.)	35,000

Data Accuracy: YELLOW -- Market size figures are analogous estimates from third-party reports; specific TAM/SAM for Spruce's indications is not publicly detailed by the company.

Competition and Substitutes

Spruce Biosciences operates in a competitive environment defined by the clinical and commercial risks inherent in developing novel therapies for rare endocrine and neurological disorders. For its lead program in CAH, the primary competition is the current standard of care: chronic, high-dose glucocorticoid replacement therapy [GlobalData]. The competitive map in CAH includes other clinical-stage companies investigating non-steroidal approaches, such as Neurocrine Biosciences with its CRF1 antagonist, crinecerfont, which has reported positive Phase 3 data.

Spruce's potential edge lies in its precision medicine strategy for MDD, developed in collaboration with HMNC Brain Health. By pairing tildacerfont with the Cortibon diagnostic, the company is attempting to carve out a niche within the broad antidepressant market [Spruce Biosciences]. The company is most exposed in its core CAH program following the recent clinical setback. Topline results from the CAHmelia-204 trial for tildacerfont in adults did not achieve the primary efficacy endpoint [Spruce Biosciences, 2026].

Data Accuracy: YELLOW -- Competitive analysis is inferred from therapeutic area context and clinical development landscape; specific named competitor data is not publicly available in the provided sources.

Opportunity

The ultimate prize for Spruce Biosciences is establishing a new standard of care in multiple rare disease markets. The headline opportunity is to become a leading commercial-stage biopharma in rare endocrine disorders, beginning with the first approved non-steroidal therapy for CAH. The company has already secured a Breakthrough Therapy designation from the FDA for its other rare disease asset, TA-ERT, for Sanfilippo syndrome type B [Healthcare-Brew, October 2025].

Growth Scenarios

Scenario	What happens	Catalyst	Why it's plausible
CAH First Approval	Tildacerfont gains FDA approval for adult CAH.	Positive top-line results from the ongoing Phase 2b pediatric trial (CAHptitude).	The drug's mechanism as a CRF1 receptor antagonist targets hormonal dysregulation [GlobalData].
Precision Psychiatry Win	Collaboration with HMNC Brain Health succeeds.	Successful completion of the Phase 2 proof-of-concept study using the Cortibon diagnostic.	Precision medicine addresses high non-response rates in depression [Spruce Biosciences].
Pipeline Expansion via TA-ERT	Enzyme replacement therapy for Sanfilippo Syndrome Type B advances.	Positive interim data from the ongoing Phase 1/2 trial (CASA).	Asset holds Breakthrough Therapy and Rare Pediatric Disease designations [Spruce Biosciences, October 2025].

Data Accuracy: YELLOW -- Scenario analysis is based on public pipeline and strategic hires; valuation comparables are illustrative, not specific to Spruce's financials.